ASCO-GI – no masking Xilio's setback
Poor efficacy clouds prospects for the company's "improved" Yervoy.
Vir shows up Sanofi
Two masked bispecific antibodies, licensed for $100m, produce promising early data.
CytomX shifts towards EpCAM
The fate of the group’s previous lead project, the Amgen-partnered CX-904, looks uncertain.
Braftovi outdoes Tafinlar in colorectal cancer
US approval gives Pfizer the first and second-line settings.
A combination Revolution
Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.
AbbVie has Met phase 3, again
The next-generation telisotuzumab adizutecan joins teliso-V in late-stage development.
The month ahead: October’s upcoming events
Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.
Gritstone has a mountain to climb with Granite
The group is persevering with Granite, but funds might be hard to come by.
